04:44 PM EDT, 08/19/2025 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) said that the European Commission granted conditional marketing authorization for Rezdiffra to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate to advanced liver fibrosis.

Rezdiffra is scheduled to launch in Germany in Q4, followed by other European markets, pending reimbursement agreements, the company said Tuesday in a statement.